Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026Business Wire • Thursday
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung CancerBusiness Wire • Wednesday
Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drugMarket Watch • Tuesday
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License ApplicationBusiness Wire • 11/15/26
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?Zacks Investment Research • 11/10/26
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in FocusZacks Investment Research • 11/05/26
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026Business Wire • 11/04/26
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaBusiness Wire • 10/25/26
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPRNewsWire • 10/24/26
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentBusiness Wire • 10/23/26
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026Business Wire • 10/22/26
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Zacks Investment Research • 10/21/26
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerPRNewsWire • 10/21/26
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerBusiness Wire • 10/21/26
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 10/19/26
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosZacks Investment Research • 10/05/26